Aceragen, Inc.

Aceragen, Inc.verified

ACGN

Price:

$0.3849

Market Cap:

$3.24M

Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. a...[Read more]

Industry

Biotechnology

IPO Date

1996-01-25

Stock Exchange

NASDAQ

Ticker

ACGN

The ROE as of December 2024 (TTM) for Aceragen, Inc. (ACGN) is -68.32%

According to Aceragen, Inc.’s latest financial reports and current stock price. The company's current ROE is -68.32%. This represents a change of 303.57% compared to the average of -16.93% of the last 4 quarters.

Aceragen, Inc. (ACGN) Historical ROE (quarterly & annually)

How has ACGN ROE performed in the past?

The mean historical ROE of Aceragen, Inc. over the last ten years is 50.74%. The current -68.32% ROE has changed -234.65% with respect to the historical average. Over the past ten years (40 quarters), ACGN's ROE was at its highest in in the March 2021 quarter at 273.59%. The ROE was at its lowest in in the March 2020 quarter at -6122.92%.

Quarterly (TTM)
Annual

Average

50.74%

Median

-57.13%

Minimum

-93.57%

Maximum

506.04%

Aceragen, Inc. (ACGN) ROE by Quarter and Year

Discovering the peaks and valleys of Aceragen, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 169.52%

Maximum Annual ROE = 506.04%

Minimum Annual Increase = -640.80%

Minimum Annual ROE = -93.57%

Quarterly (TTM)
Annual
YearROEChange
2022-60.00%-118.02%
2021333.04%169.52%
2020123.57%-75.58%
2019506.04%-640.80%
2018-93.57%52.72%
2017-61.27%64.95%
2016-37.15%-36.06%
2015-58.09%-34.75%
2014-89.03%58.53%
2013-56.16%-80.66%

Aceragen, Inc. (ACGN) Average ROE

How has ACGN ROE performed in the past?

The current ROE of Aceragen, Inc. (ACGN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

132.20%

5-year avg

161.82%

10-year avg

50.74%

Aceragen, Inc. (ACGN) ROE vs. Peers

How is ACGN’s ROE compared to its peers?

Aceragen, Inc.’s ROE is less than Addex Therapeutics Ltd (92.06%), greater than ERYTECH Pharma S.A. (-84.88%), greater than Soligenix, Inc. (-223.76%), greater than Avenue Therapeutics, Inc. (-473.61%), less than Akari Therapeutics, Plc (550.78%), less than Armata Pharmaceuticals, Inc. (89.12%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), less than Scopus BioPharma Inc. (911.69%), greater than Processa Pharmaceuticals, Inc. (-195.22%), greater than Neoleukin Therapeutics, Inc. (-8.54%), greater than Senti Biosciences, Inc. (-154.84%), greater than Hillstream BioPharma, Inc. (-172.28%), greater than SAB Biotherapeutics, Inc. (-94.37%), greater than Quoin Pharmaceuticals, Ltd. (-126.19%), greater than Cocrystal Pharma, Inc. (-94.62%), greater than iBio, Inc. (-126.61%), less than Bio-Path Holdings, Inc. (2.62%), greater than Tempest Therapeutics, Inc. (-187.44%), greater than RenovoRx, Inc. (-242.57%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.95%), greater than Acurx Pharmaceuticals, Inc. (-67679.28%),

Build a custom stock screener for Aceragen, Inc. (ACGN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aceragen, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aceragen, Inc. (ACGN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aceragen, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Aceragen, Inc.'s ROE?

How is the ROE calculated for Aceragen, Inc. (ACGN)?

What is the highest ROE for Aceragen, Inc. (ACGN)?

What is the 3-year average ROE for Aceragen, Inc. (ACGN)?

What is the 5-year average ROE for Aceragen, Inc. (ACGN)?

How does the current ROE for Aceragen, Inc. (ACGN) compare to its historical average?